-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, August 31st, on August 30th, the official website of CDE showed that Shanghai Medical’s Class 1 new drug SPH6516 tablets have been approved by clinical trials and are intended to be used for the treatment of advanced malignant solid tumors
.
Since the beginning of this year, Shanghai Pharmaceuticals has been approved for clinical use of 5 Class 1 new drugs
.
.
Since the beginning of this year, Shanghai Pharmaceuticals has been approved for clinical use of 5 Class 1 new drugs
.
SPH6516 tablets are independently developed by Shanghai Pharmaceuticals .
They have anti-tumor effects and are used for the treatment of advanced solid tumors
.
It has the advantages of high kinase inhibitory activity, good tumor cell proliferation inhibitory activity, strong tumor suppressing efficacy in vivo, and obvious synergistic effect of combined drugs
.
They have anti-tumor effects and are used for the treatment of advanced solid tumors
.
It has the advantages of high kinase inhibitory activity, good tumor cell proliferation inhibitory activity, strong tumor suppressing efficacy in vivo, and obvious synergistic effect of combined drugs
.
It is worth mentioning that in the Shanghai Pharmaceutical Innovation Drug Pipeline, multiple Class 1 new drugs are indicated for tumor diseases
.
.
Anti -tumor drugs is a hot area of current research and development of domestic and foreign pharmaceutical companies, the size of the market continued to rise
.
According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
.
According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Since the beginning of this year, Shanghai Pharmaceuticals has received clinical approval for 5 new class 1 drugs, including SPH6516 tablets, SPH3127 tablets, SPH5030 tablets, recombinant anti-CD20 humanized monoclonal antibody injection and TK216 injection
.
Among them, SPH5030 tablets are indicated for HER2-positive advanced solid tumors, and TK216 injection is indicated for relapsed and refractory Ewing's sarcoma
.
.
Among them, SPH5030 tablets are indicated for HER2-positive advanced solid tumors, and TK216 injection is indicated for relapsed and refractory Ewing's sarcoma
.
Shanghai Pharmaceuticals has been approved for clinical Class 1 new drugs since 2021
Data source: Minet database, CDE
Medical Network News, August 31st, on August 30th, the official website of CDE showed that Shanghai Medical’s Class 1 new drug SPH6516 tablets have been approved by clinical trials and are intended to be used for the treatment of advanced malignant solid tumors
.
Since the beginning of this year, Shanghai Pharmaceuticals has been approved for clinical use of 5 Class 1 new drugs
.
.
Since the beginning of this year, Shanghai Pharmaceuticals has been approved for clinical use of 5 Class 1 new drugs
.
SPH6516 tablets are independently developed by Shanghai Pharmaceuticals .
They have anti-tumor effects and are used for the treatment of advanced solid tumors
.
It has the advantages of high kinase inhibitory activity, good tumor cell proliferation inhibitory activity, strong tumor suppressing efficacy in vivo, and obvious synergistic effect of combined drugs
.
They have anti-tumor effects and are used for the treatment of advanced solid tumors
.
It has the advantages of high kinase inhibitory activity, good tumor cell proliferation inhibitory activity, strong tumor suppressing efficacy in vivo, and obvious synergistic effect of combined drugs
.
It is worth mentioning that in the Shanghai Pharmaceutical Innovation Drug Pipeline, multiple Class 1 new drugs are indicated for tumor diseases
.
.
Anti -tumor drugs is a hot area of current research and development of domestic and foreign pharmaceutical companies, the size of the market continued to rise
.
According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
.
According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Since the beginning of this year, Shanghai Pharmaceuticals has received clinical approval for 5 new class 1 drugs, including SPH6516 tablets, SPH3127 tablets, SPH5030 tablets, recombinant anti-CD20 humanized monoclonal antibody injection and TK216 injection
.
Among them, SPH5030 tablets are indicated for HER2-positive advanced solid tumors, and TK216 injection is indicated for relapsed and refractory Ewing's sarcoma
.
.
Among them, SPH5030 tablets are indicated for HER2-positive advanced solid tumors, and TK216 injection is indicated for relapsed and refractory Ewing's sarcoma
.
Shanghai Pharmaceuticals has been approved for clinical Class 1 new drugs since 2021
Data source: Minet database, CDE
Medical Network News, August 31st, on August 30th, the official website of CDE showed that Shanghai Medical’s Class 1 new drug SPH6516 tablets have been approved by clinical trials and are intended to be used for the treatment of advanced malignant solid tumors
.
Since the beginning of this year, Shanghai Pharmaceuticals has been approved for clinical use of 5 Class 1 new drugs
.
.
Since the beginning of this year, Shanghai Pharmaceuticals has been approved for clinical use of 5 Class 1 new drugs
.
SPH6516 tablets are independently developed by Shanghai Pharmaceuticals .
They have anti-tumor effects and are used for the treatment of advanced solid tumors
.
It has the advantages of high kinase inhibitory activity, good tumor cell proliferation inhibitory activity, strong tumor suppressing efficacy in vivo, and obvious synergistic effect of combined drugs
.
Medicine Medicine MedicineThey have anti-tumor effects and are used for the treatment of advanced solid tumors
.
It has the advantages of high kinase inhibitory activity, good tumor cell proliferation inhibitory activity, strong tumor suppressing efficacy in vivo, and obvious synergistic effect of combined drugs
.
It is worth mentioning that in the Shanghai Pharmaceutical Innovation Drug Pipeline, multiple Class 1 new drugs are indicated for tumor diseases
.
Disease disease disease.
Anti -tumor drugs is a hot area of current research and development of domestic and foreign pharmaceutical companies, the size of the market continued to rise
.
According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
Tumor Tumor Tumor Hospital Hospital Hospital.
According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, a year-on-year increase of 9.
63%
.
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Since the beginning of this year, Shanghai Pharmaceuticals has received clinical approval for 5 new class 1 drugs, including SPH6516 tablets, SPH3127 tablets, SPH5030 tablets, recombinant anti-CD20 humanized monoclonal antibody injection and TK216 injection
.
Among them, SPH5030 tablets are indicated for HER2-positive advanced solid tumors, and TK216 injection is indicated for relapsed and refractory Ewing's sarcoma
.
.
Among them, SPH5030 tablets are indicated for HER2-positive advanced solid tumors, and TK216 injection is indicated for relapsed and refractory Ewing's sarcoma
.
Shanghai Pharmaceuticals has been approved for clinical Class 1 new drugs since 2021
Data source: Minet database, CDE
